Skip to main content

Articles

Page 84 of 108

  1. Antitumour activity is one of the health-promoting effects attributed to the lactic acid bacteria and their products of fermentation. Previous studies in mice demonstrated that bioactive compounds released in ...

    Authors: Alejandra de Moreno de LeBlanc, Chantal Matar, Nicole LeBlanc and Gabriela Perdigón
    Citation: Breast Cancer Research 2005 7:R477
  2. Our aim was to evaluate the relationship of patients' age to histopathological features of hereditary breast tumours in a series of breast cancer families not selected for age at diagnosis. In sporadic breast ...

    Authors: Hannaleena Eerola, Päivi Heikkilä, Anitta Tamminen, Kristiina Aittomäki, Carl Blomqvist and Heli Nevanlinna
    Citation: Breast Cancer Research 2005 7:R465
  3. Gefitinib (Iressa, ZD 1839, AstraZeneca) blocks the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and inhibits proliferation of several human cancer cell types including breast cancer...

    Authors: Anne Camirand, Mahvash Zakikhani, Fiona Young and Michael Pollak
    Citation: Breast Cancer Research 2005 7:R570
  4. Studies on the association between the cytochrome P450c17α gene (CYP17) 5'-untranslated region MspA1 genetic polymorphism and breast cancer risk have yielded inconsistent results. Higher levels of estrogen have b...

    Authors: Emaculate Verla-Tebit, Shan Wang-Gohrke and Jenny Chang-Claude
    Citation: Breast Cancer Research 2005 7:R455
  5. Our goal was to generate xenograft mouse models of human breast cancer based on luciferase-expressing MDA-MB-231 tumor cells that would provide rapid mammary tumor growth; produce metastasis to clinically rele...

    Authors: Darlene E Jenkins, Yvette S Hornig, Yoko Oei, Joan Dusich and Tony Purchio
    Citation: Breast Cancer Research 2005 7:R444
  6. The purpose of this retrospective study was to determine the clinical utility of serum HER2/neu in monitoring metastatic breast cancer patients undergoing trastuzumab-based therapy and to compare these results...

    Authors: Francisco J Esteva, Carol D Cheli, Herbert Fritsche, Monica Fornier, Dennis Slamon, Robert P Thiel, Diana Luftner and Farooq Ghani
    Citation: Breast Cancer Research 2005 7:R436
  7. Epidemiological, clinical, and experimental data indicate that the risk of developing breast cancer is strongly dependent on the ovary and on endocrine conditions modulated by ovarian function, such as early m...

    Authors: Jose Russo, Raquel Moral, Gabriela A Balogh, Daniel Mailo and Irma H Russo
    Citation: Breast Cancer Research 2005 7:131
  8. Laminins are the major components of vascular and parenchymal basement membranes. We previously documented a switch in the expression of vascular laminins containing the α4 chain from predominantly laminin-9 (...

    Authors: Manabu Fujita, Natalya M Khazenzon, Shikha Bose, Kiyotoshi Sekiguchi, Takako Sasaki, William G Carter, Alexander V Ljubimov, Keith L Black and Julia Y Ljubimova
    Citation: Breast Cancer Research 2005 7:R411
  9. Although tamoxifen has been an effective treatment for breast cancer, several novel anti-oestrogen compounds have been developed with a reduced agonist profile on breast and gynaecological tissues. These inclu...

    Authors: Stephen RD Johnston
    Citation: Breast Cancer Research 2005 7:119
  10. The first Keystone symposium on the role of microenvironment in tumor induction and progression attracted 274 delegates from 13 countries to Banff in the heart of the Canadian Rockies. The meeting was organize...

    Authors: Jamie L Bascom and Paraic A Kenny
    Citation: Breast Cancer Research 2005 7:113
  11. Inhibitors of cyclo-oxygenase (COX)-2 are being extensively studied as anticancer agents. In the present study we evaluated the mechanisms by which a highly selective COX-2 inhibitor, celecoxib, affects tumor ...

    Authors: Gargi D Basu, Latha B Pathangey, Teresa L Tinder, Sandra J Gendler and Pinku Mukherjee
    Citation: Breast Cancer Research 2005 7:R422
  12. Stromal cell-derived factor (SDF)-1 (CXC chemokine ligand-12) is a member of the CXC subfamily of chemokines, which, through its cognate receptor (CXC chemokine receptor [CXCR]4), plays an important role in ch...

    Authors: Hua Kang, Gareth Watkins, Christian Parr, Anthony Douglas-Jones, Robert E Mansel and Wen G Jiang
    Citation: Breast Cancer Research 2005 7:R402
  13. The mammary gland epithelial components are thought to arise from stem cells that undergo both self-renewal and differentiation. Self-renewal has been shown to be regulated by the Hedgehog, Notch, and Wnt path...

    Authors: Suling Liu, Gabriela Dontu and Max S Wicha
    Citation: Breast Cancer Research 2005 7:86
  14. Akt1, Akt2 and Akt3 kinases are downstream components of phosphoinositol 3-kinase derived signals from receptor tyrosine kinases, which influence cell growth, proliferation and survival. Akt2 overexpression an...

    Authors: Jonas Cicenas, Patrick Urban, Vincent Vuaroqueaux, Martin Labuhn, Willy Küng, Edward Wight, Mark Mayhew, Urs Eppenberger and Serenella Eppenberger-Castori
    Citation: Breast Cancer Research 2005 7:R394
  15. N-acetyltransferase 2 is a polymorphic enzyme in humans. Women who possess homozygous polymorphic alleles have a slower rate of metabolic activation of aryl aromatic amines, one of the constituents of tobacco s....

    Authors: Timothy L Lash, Brian D Bradbury, Jemma B Wilk and Ann Aschengrau
    Citation: Breast Cancer Research 2005 7:R385
  16. c-erbB2 (also known as HER-2/neu) and topoisomerase IIα are frequently overexpressed in breast cancer. The aim of the study was to analyze retrospectively whether the expression of c-erbB2 and topoisomerase II...

    Authors: Peter Fritz, Cristina M Cabrera, Jürgen Dippon, Andreas Gerteis, Wolfgang Simon, Walter E Aulitzky and Heiko van der Kuip
    Citation: Breast Cancer Research 2005 7:R374
  17. The membrane cytoskeletal crosslinker ezrin participates in several functions including cell adhesion, motility and cell survival, and there is increasing evidence that it regulates tumour progression. However...

    Authors: Bruce E Elliott, Jalna A Meens, Sandip K SenGupta, Daniel Louvard and Monique Arpin
    Citation: Breast Cancer Research 2005 7:R365
  18. Overexpression of the HER2 proto-oncogene in human cancer cells has been associated with a poor prognosis, and survival improves with therapy targeting the HER2 gene. Animal studies and protein modeling suggest t...

    Authors: Stephanie E Nelson, Michael N Gould, John M Hampton and Amy Trentham-Dietz
    Citation: Breast Cancer Research 2005 7:R357
  19. In this issue of Breast Cancer Research, Baer and colleagues report a strong protective effect of childhood and adolescent body fatness on premenopausal breast cancer risk based on a large prospective study. Meth...

    Authors: Cecilia MK Magnusson and Andrew W Roddam
    Citation: Breast Cancer Research 2005 7:83
  20. AIB1, located at 20q12, is a member of the steroid hormone coactivator family. It contains a glutamine repeat (CAG/CAA) polymorphism at its carboxyl-terminal region that may alter the transcriptional activation ...

    Authors: Karen G Montgomery, Jiun-Horng Chang, Dorota M Gertig, Gillian S Dite, Margaret R McCredie, Graham G Giles, Melissa C Southey, John L Hopper and Ian G Campbell
    Citation: Breast Cancer Research 2005 7:R353
  21. The role of macrophages in tumor progression has generated contradictory evidence. We had previously demonstrated the ability of peritoneal macrophages from LMM3 murine mammary adenocarcinoma-bearing mice (TMp...

    Authors: Eulalia de la Torre, Lilia Davel, María A Jasnis, Tomomi Gotoh, Eugenia Sacerdote de Lustig and María E Sales
    Citation: Breast Cancer Research 2005 7:R345
  22. Dendritic cells (DCs) are antigen-presenting cells that are currently employed in cancer clinical trials. However, it is not clear whether their ability to induce tumour-specific immune responses when they are...

    Authors: Alban Gervais, Jean Levêque, Françoise Bouet-Toussaint, Florence Burtin, Thierry Lesimple, Laurent Sulpice, Jean-Jacques Patard, Noelle Genetet and Véronique Catros-Quemener
    Citation: Breast Cancer Research 2005 7:R326
  23. Mammographic density is a strong independent risk factor for breast cancer, and can be modified by hormonal exposures. Identifying genetic variants that determine increases in mammographic density in hormone u...

    Authors: Sarah J Lord, Wendy J Mack, David Van Den Berg, Malcolm C Pike, Sue A Ingles, Christopher A Haiman, Wei Wang, Yuri R Parisky, Howard N Hodis and Giske Ursin
    Citation: Breast Cancer Research 2005 7:R336
  24. Body mass index (BMI) during adulthood is inversely related to the incidence of premenopausal breast cancer, but the role of body fatness earlier in life is less clear. We examined prospectively the relation b...

    Authors: Heather J Baer, Graham A Colditz, Bernard Rosner, Karin B Michels, Janet W Rich-Edwards, David J Hunter and Walter C Willett
    Citation: Breast Cancer Research 2005 7:R314
  25. During the menstrual cycle, the mammary gland goes through sequential waves of proliferation and apoptosis. In mammary epithelial cells, hormonal and non-hormonal factors regulate apoptosis. To determine the c...

    Authors: Maria Alicia H Navarrete, Carolina M Maier, Roberto Falzoni, Luiz Gerk de Azevedo Quadros, Geraldo R Lima, Edmund C Baracat and Afonso CP Nazário
    Citation: Breast Cancer Research 2005 7:R306
  26. Adjuvant chemotherapy has been proven to reduce significantly the risk for relapse and death in women with operable breast cancer. Nevertheless, the prognosis for patients presenting with extensive axillary ly...

    Authors: Monica Fornier and Larry Norton
    Citation: Breast Cancer Research 2005 7:64
  27. We compared levels of protein and mRNA expression of three members of the claudin (CLDN) family in malignant breast tumours and benign lesions.

    Authors: Anna-Mária Tőkés, Janina Kulka, Sándor Paku, Ágnes Szik, Csilla Páska, Pál Kaposi Novák, László Szilák, András Kiss, Krisztina Bögi and Zsuzsa Schaff
    Citation: Breast Cancer Research 2005 7:R296

    The Erratum to this article has been published in Breast Cancer Research 2005 7:162

  28. The limited ability of current treatments to control metastasis and the proposed antitumor properties of specific nutrients prompted us to examine the effect of a specific formulation (nutrient supplement [NS]...

    Authors: M Waheed Roomi, Nusrath W Roomi, Vadim Ivanov, Tatiana Kalinovsky, Aleksandra Niedzwiecki and Matthias Rath
    Citation: Breast Cancer Research 2005 7:R291
  29. Tamoxifen is widely used as endocrine therapy for oestrogen-receptor-positive breast cancer. However, many of these patients experience recurrence despite tamoxifen therapy by incompletely understood mechanism...

    Authors: Pia Wegman, Linda Vainikka, Olle Stål, Bo Nordenskjöld, Lambert Skoog, Lars-Erik Rutqvist and Sten Wingren
    Citation: Breast Cancer Research 2005 7:R284
  30. Accumulating evidence suggests that fibroblasts play a pivotal role in promoting the growth of breast cancer cells. The objective of the present study was to characterize and validate an in vitro model of the int...

    Authors: Michael Samoszuk, Jenny Tan and Guillaume Chorn
    Citation: Breast Cancer Research 2005 7:R274
  31. One of the most common genetic aberrations associated with breast cancer is the amplification and overexpression of the ERBB2 proto-oncogene located at chromosome 17, bands q12-21. The amplification/overexpres...

    Authors: Marta Salido, Ignasi Tusquets, Josep M Corominas, Marta Suarez, Blanca Espinet, Cristina Corzo, Meritxell Bellet, Xavier Fabregat, Sergi Serrano and Francesc Solé
    Citation: Breast Cancer Research 2005 7:R267
  32. The prognostic significance of HER-2/neu in breast cancer is a matter of controversy. We have performed a study in 101 node-negative breast cancer patients with long-term follow-up not treated in the adjuvant set...

    Authors: Marcus Schmidt, Barbara Lewark, Nikolai Kohlschmidt, Christiane Glawatz, Erik Steiner, Berno Tanner, Henryk Pilch, Wolfgang Weikel, Heinz Kölbl and Hans-Anton Lehr
    Citation: Breast Cancer Research 2005 7:R256
  33. Inflammatory breast cancer (IBC) is both the least frequent and the most severe form of epithelial breast cancer. The diagnosis is based on clinical inflammatory signs and is reinforced by pathological finding...

    Authors: Florence Lerebours, Ivan Bieche and Rosette Lidereau
    Citation: Breast Cancer Research 2005 7:52
  34. Claudins, membrane-associated tetraspanin proteins, are normally associated with the tight junctions of epithelial cells where they confer a variety of permeability properties to the transepithelial barrier. O...

    Authors: Brigitte Blackman, Tanya Russell, Steven K Nordeen, Daniel Medina and Margaret C Neville
    Citation: Breast Cancer Research 2005 7:R248
  35. The anaphase-promoting complex (APC) is a multiprotein complex with E3 ubiquitin ligase activity, which is required for the ubiquitination of securin and cyclin-B. Moreover, the mitotic spindle checkpoint is a...

    Authors: Kwang-Hwa Park, Sung-E Choi, Minseob Eom and Yup Kang
    Citation: Breast Cancer Research 2005 7:R238
  36. Sulfotransferase 1A1 (encoded by SULT1A1) is involved in the metabolism of procarcinogens such as heterocyclic amines and polycyclic aromatic hydrocarbons, both of which are present in tobacco smoke. We recently ...

    Authors: Carmen Lilla, Angela Risch, Silke Kropp and Jenny Chang-Claude
    Citation: Breast Cancer Research 2005 7:R229
  37. About two-thirds of the excess familial risk associated with breast cancer is still unaccounted for and may be explained by multiple weakly predisposing alleles. A gene thought to be involved in low-level pred...

    Authors: Patrick R Benusiglio, Fabienne Lesueur, Craig Luccarini, Donald M Conroy, Mitul Shah, Douglas F Easton, Nick E Day, Alison M Dunning, Paul D Pharoah and Bruce AJ Ponder
    Citation: Breast Cancer Research 2005 7:R204
  38. The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant...

    Authors: Kathy Pritchard and Tim Whelan
    Citation: Breast Cancer Research 2005 7:48
  39. About 50% of patients with breast cancer have no involvement of axillary lymph nodes at diagnosis and can be considered cured after primary locoregional treatment. However, about 20–30% will experience distant...

    Authors: Ina H Benoy, Roberto Salgado, Hilde Elst, Peter Van Dam, Joost Weyler, Eric Van Marck, Simon Scharpé, Peter B Vermeulen and Luc Y Dirix
    Citation: Breast Cancer Research 2005 7:R210

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    2,432,781 downloads
    1,561 Altmetric mentions